biosurveillance
(2)
Biotia
Biotia is a New York-based health-tech company that fights infectious diseases by combining next-generation DNA sequencing with AI-driven software. Its metagenomic platform identifies bacteria, fungi, parasites and viruses - plus antimicrobial-resistance markers - from a single sample against a curated database of more than 16,000 microbial species. Spun out of the Jacobs Technion-Cornell Institute at Cornell Tech and operating a CLIA-certified lab in New York City, Biotia turns a single microbiome test into an actionable clinical report to help providers diagnose hard-to-detect infections and support pathogen surveillance from the hospital to outer space.
Niamh O'Hara
Niamh O'Hara is the co-founder and CEO of Biotia, a New York healthtech company that pairs next-generation DNA sequencing with AI to identify pathogens causing hard-to-diagnose infections. An evolutionary biologist by training, she spun the company out of Cornell Tech with Weill Cornell geneticist Christopher Mason, runs a CLIA-certified metagenomics lab in Long Island City, and is building what she calls a global microbial sequence database to catch outbreaks before they spread.